USP9X has been shown to stabilize BRCA1 and confer resistance to DNA-damaging agents, and yet its downregulation rendered BC cells resistant to tamoxifen, while its up-modulation has been found to promote centrosome amplification, chromosome instability, and higher histologic grades of BC, as well as to enhance Hippo pathway-dependent cell proliferation [46,47,48,49]. The gene discussed is USP9X; the disease is breast cancer.